PULSE BIOSCIENCES, INC.PLSEEarnings & Financial Report
Nasdaq · Health Care · Surgical & Medical Instruments & Apparatus
Colossal Biosciences Inc. is an American biotechnology and genetic engineering company working to de-extinct several extinct animals, including the woolly mammoth, the Tasmanian tiger, the northern white rhinoceros, the dire wolf, the dodo, and the moa. In 2023, it stated that it wants to have woolly mammoth hybrid calves by 2028, and wants to reintroduce them to the Arctic tundra habitat. Likewise, it launched the Tasmanian Thylacine Advisory Committee, a thylacine research project to releas...
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| ROBERT W. DUGGAN | 72.90% | 48.6M | ▲ +4.10pp | 2024-07-08 |
Insider Transactions
Net 90d: −$2.93M · buys $0 / sells $2.93MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-02-18 | Danahy Kevin Patrick | Chief Commercial Officer | Option exercise | 5.0K | $1.53 | $7.7K |
| 2026-02-18 | Danahy Kevin Patrick | Chief Commercial Officer | Sell (open market) | 5.0K | $23.64 | $118.2K |
| 2026-02-17 | Danahy Kevin Patrick | Chief Commercial Officer | Option exercise | 20.0K | $1.53 | $30.6K |
| 2026-02-17 | Danahy Kevin Patrick | Chief Commercial Officer | Sell (open market) | 20.0K | $23.63 | $472.6K |
| 2026-02-13 | Danahy Kevin Patrick | Chief Commercial Officer | Option exercise | 20.0K | $1.53 | $30.6K |
| 2026-02-13 | Danahy Kevin Patrick | Chief Commercial Officer | Sell (open market) | 20.0K | $23.53 | $470.6K |
| 2026-02-12 | Danahy Kevin Patrick | Chief Commercial Officer | Option exercise | 20.0K | $1.53 | $30.6K |
| 2026-02-12 | Danahy Kevin Patrick | Chief Commercial Officer | Sell (open market) | 20.0K | $23.37 | $467.4K |
| 2026-02-11 | Danahy Kevin Patrick | Chief Commercial Officer | Option exercise | 20.0K | $1.53 | $30.6K |
| 2026-02-11 | Danahy Kevin Patrick | Chief Commercial Officer | Sell (open market) | 20.0K | $25.20 | $504.0K |
1–10 of 14
Page 1 / 2